echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > AbbVie acquires BCMA bispecific antibody therapy for multiple myeloma

    AbbVie acquires BCMA bispecific antibody therapy for multiple myeloma

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 24, 2021, AbbVie and Teneobio jointly announced that AbbVie will exercise its exclusive right to acquire TeneoOne, a subsidiary of Teneobio and its main product under development-targeting B cell mature antigen ( BCMA)'s bispecific antibody therapy TNB-383B


    This acquisition is based on the results of an interim analysis of a Phase 1 clinical trial conducted in humans for the first time.


    ▲TNB-383B (picture source: Teneobio official website)

    In terms of safety, the most common of all grades of adverse events observed after treatment were cytokine release syndrome (CRS) (52%), fatigue (25%) and neutropenia (24%)


    Note: The original text has been deleted

    Reference materials:

    [1] AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.